Sign up to save your podcasts
Or
Share Experts Talk AML #3 : Management of Cytopenias in AML Patients on Venetoclax + Azacitidine
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk AML #3 : Management of Cytopenias in AML Patients on Venetoclax + Azacitidine
A discussion between Dr. Daniel A. Pollyea and Dr. Julie Bergeron (Fall 2021)
In this third episode of the AML podcast series, Dr. Daniel Pollyea and Dr. Julie Bergeron share some practical tips and insights regarding the management of neutropenia in patients treated with venetoclax + azacitidine. They highlight the importance of bone marrow assessments in guiding therapeutic decisions throughout treatment cycles.
Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine
Julie Bergeron, MD, FRCPC Hematologist at CEMTL Installation Maisonneuve-Rosemont Associate Professor, Université de Montréal Lead, Acute Leukemia Sub-Section of Clinical Research Unit at CEMTL Head of Service, Hematology Laboratory Optilab Montreal-CHUM
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Daniel A. Pollyea and Dr. Julie Bergeron (Fall 2021)
In this third episode of the AML podcast series, Dr. Daniel Pollyea and Dr. Julie Bergeron share some practical tips and insights regarding the management of neutropenia in patients treated with venetoclax + azacitidine. They highlight the importance of bone marrow assessments in guiding therapeutic decisions throughout treatment cycles.
Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine
Julie Bergeron, MD, FRCPC Hematologist at CEMTL Installation Maisonneuve-Rosemont Associate Professor, Université de Montréal Lead, Acute Leukemia Sub-Section of Clinical Research Unit at CEMTL Head of Service, Hematology Laboratory Optilab Montreal-CHUM
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.